Utilization of Lower-Dose Cyclobenzaprine in the Older Inpatient
The Senior Care Pharmacist · 2024
DOI: 10.4140/tcp.n.2024.249 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Senior Care Pharmacist, 2024. Verfasst von Katherine G Coli und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1 Upstate University Hospital, Pharmacy Department, Syracuse, New York. Hauptthemen laut MEDLINE: Length of Stay, Patient Readmission, Amitriptyline, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
In older inpatients, anticholinergic medications can increase the risk of complications that may increase length of stay (LOS). Cyclobenzaprine is an anticholinergic medication associated with mental status changes, falls, and injuries in older patients.
Objective
The purpose of this study is to determine whether use of a lower cyclobenzaprine dose (5 mg) compared with higher dosing (10 mg) will affect LOS, 30-day readmission rates, and need for injectable psychotropic agents in inpatients 65 years of age and older.
Methods
This was a retrospective cohort analysis comparing outcomes in patients 65 years of age and older who received either a 5 mg or 10 mg cyclobenzaprine dose during their inpatient admission over a 2.5-year period. The primary outcome was hospital LOS, adjusted using multivariate linear regression. Secondary outcomes included 30-day readmission rate adjusted using logistic regression and use of injectable antipsychotics or benzodiazepines. A sub-analysis evaluated the impact of the institution’s implementation of a geriatric prescribing context (GEM-CON) on cyclobenzaprine dose selection.
Results
The adjusted LOS was 32.7% longer (95% CI 25.9%-39.9%) for patients exposed to higher-dose cyclobenzaprine. Use of injectable antipsychotics or benzodiazepines was also significantly greater in the higher-dose group ( P < 0.001; P = 0.025). Cyclobenzaprine dose was not significantly associated with readmission on multivariate analysis (OR = 0.93, 95% CI 0.45-1.93). After GEM-CON implementation, there was a significant increase in use of the recommended lower cyclobenzaprine dose ( P < 0.001).
Conclusion
Use of lower cyclobenzaprine dosing in older inpatients is associated with reduced hospital LOS and need for injectable antipsychotics and benzodiazepines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1 Upstate University Hospital, Pharmacy Department, Syracuse, New York.
- 2 Upstate Community Hospital, Pharmacy Department, Syracuse, New York.
- 3 Binghamton University School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice, Johnson City, New York.
Zitieren
APA
Coli, K. G., Yuksel, J. M., McCall, K. L., Guan, J., Ulen, K. R., & Noviasky, J. (2024). Utilization of Lower-Dose Cyclobenzaprine in the Older Inpatient. The Senior Care Pharmacist. https://doi.org/10.4140/tcp.n.2024.249
Vancouver
Coli KG, Yuksel JM, McCall KL, Guan J, Ulen KR, Noviasky J. Utilization of Lower-Dose Cyclobenzaprine in the Older Inpatient. The Senior Care Pharmacist. 2024. doi:10.4140/tcp.n.2024.249
BibTeX
@article{Coli2024,
author = {Coli, Katherine G and Yuksel, Jaylan M and McCall, Kenneth L and Guan, Jiajie and Ulen, Kelly R and Noviasky, John},
title = {Utilization of Lower-Dose Cyclobenzaprine in the Older Inpatient},
journal = {The Senior Care Pharmacist},
year = {2024},
doi = {10.4140/tcp.n.2024.249}
}
EUVIMED